Montreal, Feb 25th, 2020 – CQDM and the Canadian Glycomics Network (GlycoNet) are pleased to announce they have formed a strategic partnership to identify and co-finance biopharmaceutical research projects in glycoscience across Canada. This partnership aims to support the development of novel technologies in drug discovery, accelerate scientific talents across Canada, and advance Canada’s position as an international leader for healthcare innovation.
“We are delighted to work with GlycoNet,” said Jesse Paterson, Senior Director of Business Development, CQDM. “As a national network with over 150 researchers across 34 institutions in Canada, GlycoNet brings world-leading expertise in glycomics to find life-saving solutions to some of the world’s biggest health challenges. The CQDM/GlycoNet alliance is both a synergistic and exciting endeavor.”
“The collaboration between CQDM and GlycoNet draws on the collective strengths of both entities, integrating research, clinical practice and education to pursue excellence in Canadian healthcare. We look forward to bringing these strengths together and help deliver tangible benefits to improve the quality of life of patients,” said Dr. Elizabeth Nanak, GlycoNet’s Executive Director.
CQDM is a biopharma-based research consortium created in 2008 with the mission to fund the development of innovative technologies to accelerate the drug discovery and development. Its business model is based on a collaborative approach bringing together world-leading pharmaceutical organizations, Canadian biotech companies as well as the Canadian and Quebec governments who share the costs of the research. CQDM uses this leverage to reduce the risks inherent to early-stage biopharmaceutical research. In doing so, CQDM bridges the funding gap needed to drive innovation across the academic and private sectors, especially where early-stage research is concerned. Over the last 10 years, CQDM has benefited from the contribution of 13 industrial members: that includes Merck, Pfizer, AstraZeneca as founding members as well as Boehringer Ingelheim, Eli Lilly Canada, GlaxoSmithKline, Janssen, Novartis Pharma Canada, Roche, Sanofi Canada, Servier, Takeda and now Amgen. CQDM also received contributions from Quebec’s Ministry of Economy and Innovation (MEI) and from the Government of Canada under the Business-Led Networks of Centres of Excellence Program (BL-NCE). Since 2008, CQDM has supported the development of 77 outstanding innovative technologies totaling $93M in funding. These R&D projects, carried out by 1,200 scientists from 83 different research institutions (40 public and 43 private) across Canada, have generated numerous economic benefits for all the stakeholders of the life science ecosystem. For more information: https://cqdm.orgen.
In 2015, the Canadian glycomics research community mobilized to form the Canadian Glycomics Network (GlycoNet), funded by the federal Networks of Centres of Excellence (NCE) program and a range of partners. The network now comprises more than 150 researchers at 34 institutions across Canada, with support from more than 140 partners. Since its inception, GlycoNet has made great strides in understanding the roles that carbohydrates play in serious diseases and advancing new therapies to treat them. Learn more about GlycoNet at www.glyconet.ca.
For further information, please contact:
Senior Director, Business Development
+1 (514) 850-7088
+1 (780) 492-4355